Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16(2): 264-269 [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264]
Corresponding Author of This Article
Jin-Qing Li, Professor, Department of Hepatobiliary, Cancer Center, Sun Yat-sen University, 651, Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. lijinq@mail.sysu.edu.cn
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2010; 16(2): 264-269 Published online Jan 14, 2010. doi: 10.3748/wjg.v16.i2.264
Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China
Ming Shi, Ji-An Chen, Xiao-Jun Lin, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Ya-Qi Zhang, Jin-Qing Li
Ming Shi, Ji-An Chen, Xiao-Jun Lin, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Ya-Qi Zhang, Jin-Qing Li, Department of Hepatobilliary, Cancer Center, Sun Yat-sen University, 651, Dongfeng Road East, Guangzhou 510060, Guangdong Province, China
Author contributions: Li JQ designed the study and analyzed data; Shi M and Chen JA took care of patients, collected and analyzed data, performed statistical analysis and wrote the manuscript (Shi M and Chen JA made equal contributions); Lin XJ, Guo RP, Yuan YF, Chen MS and Zhang YQ took care of patients, performed TACE treatments and contributed to the discussion.
Supported by The Eleventh Five-Year Key Plan of the China National Science and Technique Foundation, No. 2006BAI02A04, and the 5010 Foundation of Sun Yat-sen University, No. 2007043
Correspondence to: Jin-Qing Li, Professor, Department of Hepatobiliary, Cancer Center, Sun Yat-sen University, 651, Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. lijinq@mail.sysu.edu.cn
Telephone: +86-20-87343116 Fax: +86-20-87343480
Received: July 10, 2009 Revised: September 21, 2009 Accepted: September 28, 2009 Published online: January 14, 2010
Abstract
AIM: To identify prognostic factors from pretreatment variables of the initial transarterial chemoembolization (TACE) procedure in unresectable hepatocellular carcinoma (HCC).
METHODS: One thousand and five hundred and sixty-nine patients with unresectable HCC underwent TACE as initial treatment were retrospectively studied. Pretreatment variables of the initial TACE procedure with a P value less than 0.05 by univariate analysis were subjected to Cox proportional hazards model.
RESULTS: The median overall survival time and 1-, 5-, 10-year survival rates were 10.37 mo, 47%, 10%, and 7%, respectively. A Cox proportional hazard model showed that 8 pretreatment factors of regional lymph nodes metastasis, Child-Pugh class, macrovascular invasion, greatest dimension, α-fetoprotein (AFP), Hepatitis virus B, tumor capsule, and nodules were independent prognostic factors. Patients with multimodality therapy have better survival than those with TACE treatment only.
CONCLUSION: Tumor status, hepatic function reserve, AFP, and hepatitis virus B status were independent prognostic factors for unresectable HCC. Distant metastasis might not be a contraindication to TACE. Multimodality therapy might improve survival.
